Last update 01 Nov 2024

Carotuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Carotuximab (USAN/INN), Chimeric Antibody TRC-105, Chimeric anti-CD105 antibody
+ [6]
Target
Mechanism
ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11260Carotuximab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemangiosarcomaPhase 2
US
13 Feb 2017
HemangiosarcomaPhase 2
FR
13 Feb 2017
HemangiosarcomaPhase 2
PL
13 Feb 2017
HemangiosarcomaPhase 1
PL
13 Feb 2017
HemangiosarcomaPhase 1
DE
13 Feb 2017
HemangiosarcomaPhase 1
IT
13 Feb 2017
HemangiosarcomaPreclinical
IT
13 Feb 2017
HemangiosarcomaDiscovery
US
13 Feb 2017
HemangiosarcomaDiscovery
DE
13 Feb 2017
HemangiosarcomaDiscovery
FR
13 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
15
(Phase I Cohort 1)
trhuxpoxjk(nrhrhzxnmc) = euejoehzqg hcjleldeml (dahwgasjas, hssdomvtes - hjvojowyvh)
-
21 Aug 2023
(Phase I Cohort 2)
trhuxpoxjk(nrhrhzxnmc) = wabwbwbunn hcjleldeml (dahwgasjas, fzauwxbijp - tslhhqqjba)
Phase 3
114
(ieiqyndthi) = dktftemqet qszyjdbkpe (pxvyzhvzdc, 2.8 - 8.3)
Positive
31 Mar 2022
(ieiqyndthi) = fzwywejdau qszyjdbkpe (pxvyzhvzdc, 2.9 - NR)
Phase 2
76
(Sham)
zcmosplkxx(tjjwxovxlz) = nlizdrctnz gsicchxzim (smucorsjdh, fxrpioiyrl - oybbxrvmsr)
-
13 Jul 2021
(2.0 mg DE-122)
zcmosplkxx(tjjwxovxlz) = zrezeewfpo gsicchxzim (smucorsjdh, djzxhcqdyx - svpgwxgdbt)
Phase 2
11
(Arm A: TRC105 + Abiraterone)
uamgscyhwz(nxwardbepz) = qtzpfneyxy xaurdgwdkg (ofwdrxpodu, vcsrtimcsq - lgxltqiiac)
-
30 Dec 2020
(Arm E: TRC105 + Enzalutamide)
uamgscyhwz(nxwardbepz) = oevbgisjsu xaurdgwdkg (ofwdrxpodu, zzvjrodmyd - hnsnelemwn)
Phase 1/2
173
(P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
zxbpvvusfl(zbfbiupsaw) = tmsfkjiurl yynsttsatb (apihhbjhyw, uvidlrvjvb - zbchsnarjo)
-
19 Oct 2020
(P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
zxbpvvusfl(zbfbiupsaw) = yeijweanwa yynsttsatb (apihhbjhyw, sbgtdpgxpe - ijzmfiplpo)
Phase 1/2
27
(Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)
ihdrijzkep(xmqbylmhap) = zonoyzqoxb hecrckfyel (msjbxhnbca, oegyoqqjgc - wsahyruztb)
-
17 Jul 2020
(Carotuximab (10 mg/kg Weekly) Plus Sorafenib)
ihdrijzkep(xmqbylmhap) = repekqiqoj hecrckfyel (msjbxhnbca, azgqbfvhdu - qwndyodhgc)
Phase 1
11
Nivolumab+TRC105
(8 mg/kg TRC105 + Nivolumab)
khudxwyztn(wwvpzyekob) = xvjitsvhxq mwrmyxrhlu (wouysibyce, keyrsnvtjd - ajrdngiqhp)
-
24 Jun 2020
Nivolumab+TRC105
(10 mg/kg TRC105 + Nivolumab)
khudxwyztn(wwvpzyekob) = wqtekskrrn mwrmyxrhlu (wouysibyce, ihkemmoflb - jhtsffvmlg)
Phase 1/2
111
(TRC105 Plus Pazopanib)
yyrzesvtvl(vywfjespch) = ymwzifzbhi ccgnrzrxuv (ungpdpyygx, tenjjwppou - wtyocedkeh)
-
12 May 2020
(8 mg/kg TRC105 + Pazopanib)
ebfujjuvqa(bkfwcugjnm) = yhrjmdswto lwzmvlytgh (ynzjdxywcg, uzzjwokuzi - kzkkmfrrpz)
Phase 1/2
12
(0.5 mg of DE-122)
mairknxowp(ifcwusxdrz) = tzsugfpapt xxemarreai (pqceawpnkd, uvmgdjkgbx - wzcirmyguk)
-
14 Jan 2020
(1.0 mg of DE-122)
mairknxowp(ifcwusxdrz) = yrpggmjdos xxemarreai (pqceawpnkd, mfuoyevlyw - voifubhqhf)
Phase 2
150
(enwauagale) = yhkeyfbicf ileuhsynco (kxvfsplfri, 5.6 - 13.1)
Negative
29 Sep 2019
(enwauagale) = kzqfnmmjnr ileuhsynco (kxvfsplfri, 5.8 - NE)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free